Cortalix

Cortalix is a clinical-stage biopharmaceuticals company developing PET-imaging diagnostics, targeted radiotherapeutics and immunotherapeutics for novel targets based on its proprietary nanobody* (single-domain antibody) platforms.

Cortalix operates on a three-pillar business model:

1: Internal programs

Cortalix has a growing number of Internal Programs of selected nanobody clinical candidates targeting PDGFRA, PDGFRB, FAP, IGF2R, and EGFR for immuno-PET and immunotherapy in fibrosis and cancer. These programs are available for licensing.

2: Partner programs

Cortalix collaborates with other pharmaceutical companies and academic research groups in Partner Programs to screen and select new suitable nanobody candidates for novel targets. We can develop these nanobodies into fully-fledged radiopharmaceuticals and immunotherapeutic applications.

3: Services

Finally, we offer stand-alone nanobody selection and development projects on a fee-for-service basis for CROs, pharma companies and research groups for very different applications, including targeted therapy, immunotherapy, but also for research tools and bioanalytical applications such as immunohistochemistry, fluorescence imaging, tailored affinity columns, and ELISA development and validation.